Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jan 12:17:17562848231222332.
doi: 10.1177/17562848231222332. eCollection 2024.

Treatment persistence and switching patterns of ABP 501 in European patients with inflammatory bowel disease

Ran Jin  1 , Silvia Kruppert  2 , Florian Scholz  2 , Isabelle Bardoulat  3 , Khalil Karzazi  3 , Greg Kricorian  4 , James L O'Kelly  4 , Walter Reinisch  5
Affiliations

Treatment persistence and switching patterns of ABP 501 in European patients with inflammatory bowel disease

Ran Jin et al. Therap Adv Gastroenterol. .

Abstract

Background: Approval of the adalimumab (ADA) biosimilar ABP 501 for inflammatory bowel disease (IBD) indications was based on the principle of extrapolation, without indication-specific clinical trial data.

Objectives: To evaluate the real-world treatment patterns of ABP 501 in patients with IBD.

Design: Retrospective analysis of pharmacy claims data from Germany and France.

Methods: Continuously insured adult IBD patients who initiated ABP 501 between October 2018 and March 2020 were included. Treatment persistence, adherence, and post-ABP 501 switching patterns were evaluated for two mutually exclusive groups: ADA-naïve patients (i.e. no baseline use of ADA products) and ADA-experienced patients (i.e. previously treated with ADA products).

Results: A total of 3362 German patients and 733 French patients were included, with 54.4% and 65.3% being ADA-naïve patients, respectively. Median persistence (95% CI) on ABP 501 was 10.9 months (9.8-11.6) in ADA-naïve patients and 14.2 months (12.7-15.2) in ADA-experienced patients in Germany; for the French cohort, ADA-naïve and -experienced patients had median persistence of 12.8 months (10.2-14.7) and 11.5 months (8.8-14.4), respectively. During the first 12 months of ABP 501 initiation, 53.7% of German patients and 51.0% of French patients were adherent to the therapy. About 20% of patients in both countries switched from ABP 501 to another targeted therapy. In the German cohort, ADA-naïve patients most frequently switched to non-tumor necrosis factor inhibitor biologics, but ADA-experienced patients most commonly switched to reference product (RP); in the French cohort, patients most often switched to RP regardless of prior exposure to ADA products.

Conclusion: About 50% of patients persisted on and were adherent to ABP 501 therapy during the first 12 months after treatment initiation in two large European countries. Post-ABP 501, switching patterns varied between countries, indicating diversified treatment practices warranting further research on reason(s) for switching and potential overall treatment outcomes.

Keywords: ABP 501; adalimumab biosimilar; adalimumab-atto; inflammatory bowel disease; persistence; real-world evidence; treatment pattern.

PubMed Disclaimer

Conflict of interest statement

R. Jin, G. Kricorian, and J. L. O’Kelly are employees and stockholders of Amgen. S. Kruppert, F. Scholz, I. Bardoulat, and K. Karzazi are employees of IQVIA Real World Solutions. W. Reinishch has received research grants from Takeda, AbbVie, Pfizer, Janssen, consulting fees from AbbVie, AOP Orphan, Bioclinica, Bristol Myers Squibb, Calyx, Eli Lilly, Galapagos, Gilead, Index Pharma, Janssen, Landos Biopharma, Microbiotica, MSD, Pfizer, Protagonist, Seres Therapeutics, Takeda, Teva Pharma, and speakers bureau fees from AbbVie, Celltrion, Janssen, Galapagos, MSD, Takeda.

Figures

Figure 1.
Figure 1.
Study design. LRx, longitudinal prescription data.
Figure 2.
Figure 2.
Kaplan–Meier curve of treatment persistence of biosimilar ABP 501 among German (a) and French (b) patients with inflammatory bowel disease. ADA, adalimumab.
See this image and copyright information in PMC

References

    1. Abraham C, Cho JH. IL-23 and autoimmunity: new insights into the pathogenesis of inflammatory bowel disease. Annu Rev Med 2009; 60: 97–110. - PubMed
    1. De Boer AG, Bennebroek Evertsz F, Stokkers PC, et al.. Employment status, difficulties at work and quality of life in inflammatory bowel disease patients. Eur J Gastroenterol Hepatol 2016; 28: 1130–1136. - PubMed
    1. Argyriou K, Kapsoritakis A, Oikonomou K, et al.. Disability in patients with inflammatory bowel disease: correlations with quality of life and patient’s characteristics. Can J Gastroenterol Hepatol 2017; 2017: 6138105. - PMC - PubMed
    1. Vogelaar L, Spijker AV, van der Woude CJ. The impact of biologics on health-related quality of life in patients with inflammatory bowel disease. Clin Exp Gastroenterol 2009; 2: 101–109. - PMC - PubMed
    1. Lowe SC, Sauk JS, Limketkai BN, et al.. Declining rates of surgery for inflammatory bowel disease in the era of biologic therapy. J Gastrointest Surg 2021; 25: 211–219. - PubMed